Immunogenic cell death in cancer immunotherapy

키워드

참고문헌 (122)

1. Swann JB, "Immune surveillance of tumors", J Clin Invest, 117, pp.1137~1146 (2007)
2. Verma NK, "Obstacles for T-lymphocytes in the tumour microenvironment : therapeutic challenges, advances and opportunities beyond immune checkpoint", EBioMedicine, 83, pp.104216~ (2022)
3. Wang M, "Therapeutic strategies to remodel immunologically cold tumors", Clin Transl Immunology, 9, pp.e1226~ (2020)
4. Duan Q, "Turning cold into hot : firing up the tumor microenvironment", Trends Cancer, 6, pp.605~618 (2020)
5. Zhang J, "Turning cold tumors hot : from molecular mechanisms to clinical applications", Trends Immunol, 43, pp.523~545 (2022)
6. Kaufman HL, "Oncolytic viruses : a new class of immunotherapy drugs", Nat Rev Drug Discov, 14, pp.642~662 (2015)
7. Li K, "Targeting the innate immune system with nanoparticles for cancer immunotherapy", J Mater Chem B, 10, pp.1709~1733 (2022)
8. Bazak R, "Cancer active targeting by nanoparticles : a comprehensive review of literature", J Cancer Res Clin Oncol, 141, pp.769~784 (2015)
9. Rosenbaum SR, "Fueling the fire : inflammatory forms of cell death and implications for cancer immunotherapy", Cancer Discov, 11, pp.266~281 (2021)
10. Liu M, "Regulated lytic cell death in breast cancer", Cell Biol Int, 46, pp.12~33 (2022)
11. Chen GY, "Sterile inflammation : sensing and reacting to damage", Nat Rev Immunol, 10, pp.826~837 (2010)
12. Krysko DV, "Immunogenic cell death and DAMPs in cancer therapy", Nat Rev Cancer, 12, pp.860~875 (2012)
13. Ahmed A, "Targeting immunogenic cell death in cancer", Mol Oncol, 14, pp.2994~3006 (2020)
14. Serrano-Del Valle A, "Immunogenic cell death and immunotherapy of multiple myeloma", Front Cell Dev Biol, 7, pp.50~ (2019)
15. Legrand AJ, "The diversification of cell death and immunity : memento mori", Mol Cell, 76, pp.232~242 (2019)
16. Bustin M, "Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins", Mol Cell Biol, 19, pp.5237~5246 (1999)
17. Lui G, "HMGB1", RAGE signaling and pro-inflammatory cytokine responses in non-HIV adults with active pulmonary tuberculosis, 2016, pp.11, e0159132~
18. Li L, "The regulatory role of high-mobility group protein 1 in sepsis-related immunity", Front Immunol, 11, pp.601815~ (2020)
19. Ge Y, "The effect and regulatory mechanism of high mobility group box-1protein on immune cells in inflammatory diseases", Cells, 10, pp.1044~ (2021)
20. Klune JR, "HMGB1 : endogenous danger signaling", Mol Med, 14, pp.476~484 (2008)
21. Pandya UM, "The biophysical interaction of the danger-associated molecular pattern(DAMP)calreticulin with the pattern-associated molecular pattern(PAMP)lipopolysaccharide", Int J Mol Sci, 20, pp.408~ (2019)
22. Obeid M, "Ecto-calreticulin in immunogenic chemotherapy", Immunol Rev, 220, pp.22~34 (2007)
23. Wemeau M, "Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia", Cell Death Dis, 1, pp.e104~ (2010)
24. Obeid M, "Calreticulin exposure dictates the immunogenicity of cancer cell death", Nat Med, 13, pp.54~61 (2007)
25. Zunino B, "Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90", Oncogene, 35, pp.261~268 (2016)
26. Murshid A, "The role of heat shock proteins in antigen cross presentation", Front Immunol, 3, pp.63~ (2012)
27. van Eden W, "Heat-shock proteins induce T-cell regulation of chronic inflammation", Nat Rev Immunol, 5, pp.318~330 (2005)
28. Kovalchin JT, "In vivo treatment of mice with heat shock protein, gp 96, improves survival of skin grafts with minor and major antigenic disparity", Transpl Immunol, 15, pp.179~185 (2006)
29. Amores-Iniesta J, "Extracellular ATP Activates the NLRP3 inflammasome and is an early danger signal of skin allograft rejection", Cell Rep, 21, pp.3414~3426 (2017)
30. Venereau E, "DAMPs from cell death to new life", Front Immunol, 6, pp.422~ (2015)
31. Ghiringhelli F, "Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors", Nat Med, 15, pp.1170~1178 (2009)
32. Kepp O, "ATP and cancer immunosurveillance", EMBO J, 40, pp.e108130~ (2021)
33. Nyboe Andersen N, "Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease : nationwide Danish cohort study", BMJ, 350, pp.h2809~ (2015)
34. Parameswaran N, "Tumor necrosis factor-alpha signaling in macrophages", Crit Rev Eukaryot Gene Expr, 20, pp.87~103 (2010)
35. Cervera-Carrascon V, "TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade", Oncoimmunology, 7, pp.e1412902~ (2018)
36. Jiang C, "Tumor vasculature-targeted recombinant mutated human TNF-alpha enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models", PLoS One, 9, pp.e87036~ (2014)
37. Egberts JH, "Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis", Cancer Res, 68, pp.1443~1450 (2008)
38. Cruceriu D, "The dual role of tumor necrosis factoralpha(TNF-alpha)in breast cancer : molecular insights and therapeutic approaches", Cell Oncol(Dordr), 43, pp.1~18 (2020)
39. Zhang W, "IL-1 signaling in tumor microenvironment", Adv Exp Med Biol, 1240, pp.1~23 (2020)
40. Chen L, "Myeloid differentiation primary response protein 88(MyD88) : the central hub of TLR", IL-1R signaling, 2020, pp.63, 13316~13329
41. Nakamura K, "Targeting cancerrelated inflammation in the era of immunotherapy", Immunol Cell Biol, 95, pp.325~332 (2017)
42. Chen CJ, "Identification of a key pathway required for the sterile inflammatory response triggered by dying cells", Nat Med, 13, pp.851~856 (2007)
43. Platanias LC, "Mechanisms of type-I-and type-II-interferon-mediated signalling", Nat Rev Immunol, 5, pp.375~386 (2005)
44. Zhu Y, "STING : a master regulator in the cancer-immunity cycle", Mol Cancer, 18, pp.152~ (2019)
45. Vacchelli E, "Autocrine signaling of type 1interferons in successful anticancer chemotherapy", Oncoimmunology, 4, pp.e988042~ (2015)
46. Zhang S, "Systemic interferon-gamma increases MHC class I expression and T-cell infiltration in cold tumors : results of a phase 0clinical trial", Cancer Immunol Res, 7, pp.1237~1243 (2019)
47. Dovhey SE, "Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line", Cancer Res, 60, pp.5789~5796 (2000)
48. Gangaplara A, "Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment", PLoS Pathog, 14, pp.e1006985~ (2018)
49. Coughlin CM, "Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis", Immunity, 9, pp.25~34 (1998)
50. Sistigu A, "Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy", Nat Med, 20, pp.1301~1309 (2014)
51. Karsch-Bluman A, "Tissue necrosis and its role in cancer progression", Oncogene, 38, pp.1920~1935 (2019)
52. Koren E, "Modes of Regulated cell death in cancermodes of regulated cell death in cancer", Cancer Discov, 11, pp.245~265 (2021)
53. Galluzzi L, "Molecular mechanisms of cell death : recommendations of the nomenclature committee on cell death 2018", Cell Death Differ, 25, pp.486~541 (2018)
54. Cai Z, "Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis", Nat Cell Biol, 16, pp.55~65 (2014)
55. Kaiser WJ, "Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL", J Biol Chem, 288, pp.31268~31279 (2013)
56. Zhang Y, "Plasma membrane changes during programmed cell deaths", Cell Res, 28, pp.9~21 (2018)
57. Günther C, "Caspase-8regulates TNF-α-induced epithelial necroptosis and terminal ileitis", Nature, 477, pp.335~339 (2011)
58. Berghe TV, "Regulated necrosis : the expanding network of non-apoptotic cell death pathways", Nat Rev Mol Cell Biol, 15, pp.135~147 (2014)
59. Murphy JM, "The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism", Immunity, 39, pp.443~453 (2013)
60. Aaes TL, "Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity", Cell Rep, 15, pp.274~287 (2016)
61. Park HH, "RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment", Mol Cancer, 20, pp.107~ (2021)
62. Nicolè L, "Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3+ and CD8+ T cell density and predict prognosis in hepatocellular carcinoma", J Immunother Cancer, 10, pp.e004031~ (2022)
63. Koo GB, "Methylationdependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics", Cell Res, 25, pp.707~725 (2015)
64. Snyder AG, "Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity", Sci immunol, 4, pp.eaaw2004~ (2019)
65. Werthmöller N, "Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide-and T-cell-dependent manner", Cell Death Dis, 6, pp.e1761~ (2015)
66. Jiang X, "Ferroptosis : mechanisms, biology and role in disease", Nat Rev Mol Cell Biol, 22, pp.266~282 (2021)
67. Lewerenz J, "Cooperative action of glutamate transporters and cystine", glutamate antiporter system Xc–protects from oxidative glutamate toxicity, 2006, pp.98, 916~925
68. Brigelius-Flohé R, "Glutathione peroxidases", Biochim Biophys Acta, 1830, pp.3289~3303 (2013)
69. Feng H, "Unsolved mysteries : how does lipid peroxidation cause ferroptosis?", PLoS Biol, 16, pp.e2006203~ (2018)
70. Dixon SJ, "Ferroptosis : an iron-dependent form of nonapoptotic cell death", Cell, 149, pp.1060~1072 (2012)
71. Louandre C, "Irondependent cell death of hepatocellular carcinoma cells exposed to sorafenib", Int J Cancer, 133, pp.1732~1742 (2013)
72. Yang WS, "Regulation of ferroptotic cancer cell death by GPX4", Cell, 156, pp.317~331 (2014)
73. Yang WS, "Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis", Proc Natl Acad Sci U S A, 113, pp.E4966~E4975 (2016)
74. Gaschler MM, "FINO2initiates ferroptosis through GPX4 inactivation and iron oxidation", Nat Chem Biol, 14, pp.507~515 (2018)
75. Manz DH, "Iron and cancer : recent insights", Ann N Y Acad Sci, 1368, pp.149~161 (2016)
76. Whitnall M, "A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics", Proc Natl Acad Sci U S A, 103, pp.14901~14906 (2006)
77. Chen SJ, "Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo", Oncotarget, 7, pp.49310~49321 (2016)
78. Wang W, "CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy", Nature, 569, pp.270~274 (2019)
79. Bordini J, "Iron induces cell death and strengthens the efficacy of antiandrogen therapy in prostate cancer models", Clin Cancer Res, 26, pp.6387~6398 (2020)
80. Zou Y, "A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis", Nat Commun, 10, pp.1617~ (2019)
81. Gout P, "Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc-cystine transporter : a new action for an old drug", Leukemia, 15, pp.1633~1640 (2001)
82. Yu Y, "The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents", Mol Cell Oncol, 2, pp.e1054549~ (2015)
83. Hassannia B, "Targeting ferroptosis to iron out cancer", Cancer Cell, 35, pp.830~849 (2019)
84. Wen Q, "The release and activity of HMGB1 in ferroptosis", Biochem Biophys Res Commun, 510, pp.278~283 (2019)
85. Ye F, "HMGB1 regulates erastin-induced ferroptosis via RAS-JNK", p38 signaling in HL-60, Am J Cancer Res, pp.2019, 9[DOI]
86. Luo X, "Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2", Cell Death Differ, 28, pp.1971~1989 (2021)
87. Raskov H, "Cytotoxic CD8+ T cells in cancer and cancer immunotherapy", Br J Cancer, 124, pp.359~367 (2021)
88. Efimova I, "Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity", J Immunother Cancer, 8, pp.e001369~ (2020)
89. Song J, "The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity", EMBO Rep, 22, pp.e51162~ (2021)
90. Jiang Z, "TYRO3 induces anti-PD-1", PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis, 2021, pp.131, e139434~
91. Wang W, "CD8(+)T cells regulate tumour ferroptosis during cancer immunotherapy", Nature, 569, pp.270~274 (2019)
92. Lang X, "Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11ferroptosis connects radiotherapy and immunotherapy", Cancer Discov, 9, pp.1673~1685 (2019)
93. Wang H, "Emerging mechanisms and targeted therapy of ferroptosis in cancer", Mol Ther, 29, pp.2185~2208 (2021)
94. Aglietti RA, "Recent Insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions", Trends Immunol, 38, pp.261~271 (2017)
95. Erkes DA, "Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis", Cancer Discov, 10, pp.254~269 (2020)
96. Yang D, "Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock", Immunity, 43, pp.923~932 (2015)
97. Fink SL, "Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages", Cell Microbiol, 8, pp.1812~1825 (2006)
98. Yu P, "Pyroptosis : mechanisms and diseases", Signal Transduct Target Ther, 6, pp.1~21 (2021)
99. Platnich JM, "NOD-like receptors and inflammasomes : a review of their canonical and non-canonical signaling pathways", Arch Biochem Biophys, 670, pp.4~14 (2019)
100. Shi J, "Inflammatory caspases are innate immune receptors for intracellular LPS", Nature, 514, pp.187~192 (2014)
101. Hornung V, "AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC", Nature, 458, pp.514~518 (2009)
102. Chae JJ, "The B30. 2domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1βproduction", Proc Natl Acad Sci U S A, 103, pp.9982~9987 (2006)
103. Lu A, "Unified polymerization mechanism for the assembly of ASCdependent inflammasomes", Cell, 156, pp.1193~1206 (2014)
104. Liu X, "Inflammasomeactivated gasdermin D causes pyroptosis by forming membrane pores", Nature, 535, pp.153~158 (2016)
105. Kayagaki N, "Caspase-11cleaves gasdermin D for non-canonical inflammasome signalling", Nature, 526, pp.666~671 (2015)
106. Shi J, "Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death", Nature, 526, pp.660~665 (2015)
107. Wang Y, "Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin", Nature, 547, pp.99~103 (2017)
108. Ding J, "Pore-forming activity and structural autoinhibition of the gasdermin family", Nature, 535, pp.111~116 (2016)
109. Jiang M, "The caspase-3", GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer, 2020, pp.6, 1~11
110. Aizawa E, "GSDMEdependent incomplete pyroptosis permits selective IL-1αrelease under caspase-1 inhibition", iScience, 23, pp.101070~ (2020)
111. Zhang Z, "Gasdermin E suppresses tumour growth by activating anti-tumour immunity", Nature, 579, pp.415~420 (2020)
112. Zhou Z, "Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells", Science, 368, pp.eaaz7548~ (2020)
113. Wang Q, "A bioorthogonal system reveals antitumour immune function of pyroptosis", Nature, 579, pp.421~426 (2020)
114. Li S, "Pyroptosis predicts immunotherapy outcomes across multiple cancer types", Clin Immunol, 245, pp.109163~ (2022)
115. Pauken KE, "Overcoming T cell exhaustion in infection and cancer", Trends Immunol, 36, pp.265~276 (2015)
116. Lu H, "VTX-2337is a novel TLR8 agonist that activates NK cells and augments ADCC", Clin Cancer Res, 18, pp.499~509 (2012)
117. Dietsch GN, "Coordinated activation of toll-like receptor8(TLR8)and NLRP3 by the TLR8 agonist, VTX-2337, ignites tumoricidal natural killer cell activity", PLoS One, 11, pp.e0148764~ (2016)
118. Monk BJ, "A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer : a gynecologic oncology group partners study", Ann Oncol, 28, pp.996~1004 (2017)
119. Gabrilovich DI, "Myeloid-derived suppressor cells as regulators of the immune system", Nat Rev Immunol, 9, pp.162~174 (2009)
120. Coward J, "Interleukin-6 as a therapeutic target in human ovarian cancer", Clin Cancer Res, 17, pp.6083~6096 (2011)
121. Dijkgraaf EM, "A phase I trial combining carboplatin", doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer, 2015, pp.26, 2141~2149
122. Birmpilis AI, "Immunogenic cell death, damps and prothymosin alpha as a putative anticancer immune response biomarker", Cells, 11, pp.1415~ (2022)

관련 논문AI추천